344 related articles for article (PubMed ID: 22156369)
21. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
André LM; van Cruchten RTP; Willemse M; Wansink DG
PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
[TBL] [Abstract][Full Text] [Related]
22. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
[TBL] [Abstract][Full Text] [Related]
23. Dysfunction of protein homeostasis in myotonic dystrophies.
Meola G; Jones K; Wei C; Timchenko LT
Histol Histopathol; 2013 Sep; 28(9):1089-98. PubMed ID: 23536431
[TBL] [Abstract][Full Text] [Related]
24. Expanded CUG repeats Dysregulate RNA splicing by altering the stoichiometry of the muscleblind 1 complex.
Paul S; Dansithong W; Jog SP; Holt I; Mittal S; Brook JD; Morris GE; Comai L; Reddy S
J Biol Chem; 2011 Nov; 286(44):38427-38438. PubMed ID: 21900255
[TBL] [Abstract][Full Text] [Related]
25. Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
Klein AF; Gasnier E; Furling D
Biochimie; 2011 Nov; 93(11):2006-12. PubMed ID: 21763392
[TBL] [Abstract][Full Text] [Related]
26. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy.
Orengo JP; Chambon P; Metzger D; Mosier DR; Snipes GJ; Cooper TA
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2646-51. PubMed ID: 18272483
[TBL] [Abstract][Full Text] [Related]
27. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
28. High-throughput kinome-RNAi screen identifies protein kinase R activator (PACT) as a novel genetic modifier of CUG foci integrity in myotonic dystrophy type 1 (DM1).
Neault N; O'Reilly S; Baig AT; Plaza-Diaz J; Azimi M; Farooq F; Baird SD; MacKenzie A
PLoS One; 2021; 16(9):e0256276. PubMed ID: 34520479
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats.
Dhaenens CM; Schraen-Maschke S; Tran H; Vingtdeux V; Ghanem D; Leroy O; Delplanque J; Vanbrussel E; Delacourte A; Vermersch P; Maurage CA; Gruffat H; Sergeant A; Mahadevan MS; Ishiura S; Buée L; Cooper TA; Caillet-Boudin ML; Charlet-Berguerand N; Sablonnière B; Sergeant N
Exp Neurol; 2008 Apr; 210(2):467-78. PubMed ID: 18177861
[TBL] [Abstract][Full Text] [Related]
30. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
31. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive.
Childs-Disney JL; Hoskins J; Rzuczek SG; Thornton CA; Disney MD
ACS Chem Biol; 2012 May; 7(5):856-62. PubMed ID: 22332923
[TBL] [Abstract][Full Text] [Related]
32. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.
Lin X; Miller JW; Mankodi A; Kanadia RN; Yuan Y; Moxley RT; Swanson MS; Thornton CA
Hum Mol Genet; 2006 Jul; 15(13):2087-97. PubMed ID: 16717059
[TBL] [Abstract][Full Text] [Related]
33. Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5.
Jones K; Wei C; Schoser B; Meola G; Timchenko N; Timchenko L
Proc Natl Acad Sci U S A; 2015 Jun; 112(26):8041-5. PubMed ID: 26080402
[TBL] [Abstract][Full Text] [Related]
34. The protein factors MBNL1 and U2AF65 bind alternative RNA structures to regulate splicing.
Warf MB; Diegel JV; von Hippel PH; Berglund JA
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9203-8. PubMed ID: 19470458
[TBL] [Abstract][Full Text] [Related]
35. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
[TBL] [Abstract][Full Text] [Related]
36. Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.
Wong CH; Nguyen L; Peh J; Luu LM; Sanchez JS; Richardson SL; Tuccinardi T; Tsoi H; Chan WY; Chan HY; Baranger AM; Hergenrother PJ; Zimmerman SC
J Am Chem Soc; 2014 Apr; 136(17):6355-61. PubMed ID: 24702247
[TBL] [Abstract][Full Text] [Related]
37. MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity.
Yadava RS; Kim YK; Mandal M; Mahadevan K; Gladman JT; Yu Q; Mahadevan MS
Hum Mol Genet; 2019 Jul; 28(14):2330-2338. PubMed ID: 30997488
[TBL] [Abstract][Full Text] [Related]
38. Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Warf MB; Nakamori M; Matthys CM; Thornton CA; Berglund JA
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18551-6. PubMed ID: 19822739
[TBL] [Abstract][Full Text] [Related]
39. Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene.
Llamusí B; Artero R
Curr Genomics; 2008 Dec; 9(8):509-16. PubMed ID: 19516957
[TBL] [Abstract][Full Text] [Related]
40. Transcriptionally correlated subcellular dynamics of MBNL1 during lens development and their implication for the molecular pathology of myotonic dystrophy type 1.
Coleman SM; Prescott AR; Sleeman JE
Biochem J; 2014 Mar; 458(2):267-80. PubMed ID: 24354850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
